Donald P. Lehr serves as Senior Vice President, Chief Legal Officer, and Corporate Secretary at Precigen, Inc., a leading biotechnology company focused on developing innovative therapies in immuno-oncology, autoimmune disorders, and infectious diseases. In this pivotal role, he oversees all legal, compliance, intellectual property, and corporate governance matters, providing strategic counsel to the executive team and board of directors. Lehr's leadership ensures Precigen navigates complex regulatory landscapes, including FDA approvals, patent protections, and securities compliance, while supporting the company's mission to advance synthetic biology solutions. With over 30 years of experience in the life sciences industry, Lehr has held senior legal positions at prominent biotech firms. Prior to joining Precigen (formerly Intrexon Corporation), he was General Counsel at Synthetic Genomics, Inc., where he managed global legal operations, mergers and acquisitions, and strategic partnerships. Earlier in his career, he served as Vice President and Deputy General Counsel at Human Genome Sciences, Inc., contributing to landmark deals such as the $3.6 billion acquisition by GlaxoSmithKline. His expertise spans corporate transactions, licensing agreements, and litigation, honed through roles at law firms like Hogan & Hartson (now Hogan Lovells). Lehr's notable achievements include guiding multiple initial public offerings, venture capital financings totaling over $1 billion, and high-stakes collaborations with pharmaceutical giants. At Precigen, he has been instrumental in securing key intellectual property portfolios and advancing clinical programs through rigorous legal frameworks. A graduate of Georgetown University Law Center and a member of the bars in multiple states, Lehr is recognized for his pragmatic approach to fostering innovation while mitigating risks in the fast-evolving biotech sector.